THE EVALUATION OF THE INTESTINAL BILE ACID TRANSPORT (IBAT) INHIBITOR LUM001 IN THE REDUCTION OF PRURITUS IN ALAGILLE SYNDROME, A CHOLESTATIC LIVER DISEASE

Registry ID

LUM001-301

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

LUMENA PHARMACEUTICALS INC

Start date

2015-11-29

Completion date

2016-11-28

Last update

2014-02-06

Conditions

• ALAGILLE SYNDROME
• CHOLESTATIC LIVER DISEASE

Related clinical trials

• A MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME

View on source registry